BGB-A317-B167-101
22 Feb 2023
Trial Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors.
Acronym:
BGB-A317-B167-101
ACTRN/NCT /ethics:
NCT05494762
Scientific title:
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
Sponsor / Cooperative group:
BeiGene
Trial & Patient Characteristics
| Cancer Type | Solid Tumor |
|---|---|
| Trial Type | Interventional |
| Phase | Phase I |
| Age Range | 18 Years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2022-08-25 |
| Anticipated End Date | 2025-08-05 |
Participating Hospitals
| Hospital | Icon Cancer Centre - Tennyson and Windsor Garden |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| Sue.Yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Francis Parnis |
| Recruitment Status | Recruiting |